A Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of the BRAF Inhibitor GSK2118436 in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Dabrafenib (Primary) ; Midazolam
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 06 Apr 2012 Actual patient number 184 added as reported by ClinicalTrials.gov.
- 06 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.